Regeneron pharmaceuticals (regn) faces securities class action after losing $9 billion value following q3 2024 earnings report – hagens berman

San francisco, ca / access newswire / february 11, 2025 / regeneron pharmaceuticals, inc. (nasdaq:regn) is facing mounting pressure on multiple fronts. following disappointing sales figures and ongoing legal challenges, analysts td cowen recently lowered its price target for regeneron to $1,030 from $1,230.
REGN Ratings Summary
REGN Quant Ranking